An Investigator initiated, open-label, Single arm, non-randomized clinical study to evaluate the effectiveness, tolerability and safety of Besifloxacin hydrochloride in the treatment of subjects suffering from Gram-negative facial folliculitis. - Gram Negative Folliculitis (GNF)

Start Date03 May 2019

Sponsor / Collaborator-

NCT04542759 / CompletedPhase 1IIT

Effect of Topical Besifloxacin on Ocular Surface Bacterial Microbiota Prior to Cataract Surgery

Describe the efficacy of the use of topical besifloxacin in reducing the conjunctival microbiota as a prophylactic measure in patients scheduled for cataract surgery.

Start Date01 Jan 2017

Sponsor / Collaborator-

NCT02497365 / CompletedNot ApplicableIIT

Besifloxacin Ophthalmic Suspension in Patients With Bacterial Keratitis: A Prospective, Randomized Clinical Study

This is a study comparing a new treatment for bacterial keratitis (also known as corneal ulcers) with the current standard of care. It is a randomized trial, and the investigators plan to test whether besifloxacin (a new antibiotic) in comparison to the current standard of treatment, fortified antibiotic drops (cefazolin and tobramycin).

Start Date01 Sep 2015

Sponsor / Collaborator

McGill University Health Center

100 Clinical Results associated with Besifloxacin Hydrochloride

100 Translational Medicine associated with Besifloxacin Hydrochloride

100 Patents (Medical) associated with Besifloxacin Hydrochloride

109

Literatures (Medical) associated with Besifloxacin Hydrochloride

01 Jan 2022·Drug Delivery and Translational ResearchQ3 · MEDICINE

Besifloxacin-loaded ocular nanoemulsions: design, formulation and efficacy evaluation

Q3 · MEDICINE

Article

Author: Kassaee, Seyedeh Negin ; Mahboobian, Mohammad Mehdi

The purpose of this study was to develop and evaluate nanoemulsions (NEs) containing besifloxacin for ocular drug delivery. Pseudo ternary phase diagrams were constructed using Triacetin (oil), Cremophor^® RH 40 (surfactant), and Transcutol^®P (co-surfactant) to identify NE regions. Six formulations were developed by low-energy emulsification method and then evaluated for size, refractive index, pH, osmolality, viscosity, and drug release. After accelerated physical stability and bovine conrneal permeation studies, NE2 was chosen as optimized formulation forantimicrobial efficacy, and hen's egg test-chorioallantoic membrane (HET-CAM) tests. The particle size of optimum NE was 14 nm with a narrow size distribution. Moreover, other physicochemical characterizations were in the acceptable range for ocular administration. Besifloxacin-loaded NEs demonstrated sustained release pattern and 1.7-fold higher permeation compared with the control suspension in the ex vivo transcorneal permeation study. HET-CAM test indicated no irritation, and HL% revealed no damage to the tissue, so the optimum NE is well tolerated by the eye. In vitro antimicrobial evaluation, showed comparative efficacy of lower drug-loaded NE (0.2%) versus 0.6% besifloxacin suspension (equal concentration to commercial besifloxacin eye drop). In conclusion, besifloxacin-loaded NEs could be considered as a suitable alternative to the marketed suspension for treating bacterial eyeinfections.

01 Nov 2021·Journal of Chromatography BQ3 · MEDICINE

A novel, sensitive, and widely accessible besifloxacin quantification method by HPLC-fluorescence: Application to an ocular pharmacokinetic study

Q3 · MEDICINE

Article

Author: Kohane, Daniel S ; Kanu, Levi N ; Romanowski, Eric G ; Ciolino, Joseph B ; Kuang, Liangju ; Ross, Amy E ; Kowalski, Regis P

Besifloxacin has been embraced for the treatment of ocular bacterial infections. While LC-MS/MS has been used in investigating BSF pharmacokinetics, those costly instruments are not universally available and have complicated requirements for operation and maintenance. Additionally, pharmacokinetics of besifloxacin in dose-intense regimens are still unknown. Herein, a new quantification method was developed employing the widely accessible HPLC with fluorescence detection and applied to an ocular pharmacokinetic study with an intense regimen. Biosamples were pre-treated using protein precipitation. Chromatographic separation was achieved on a C18 column using mobile phase of 0.1% trifluoroacetic acid and acetonitrile. To address the weak fluorescence issue of besifloxacin, effects of detection parameters, elution pattern, pH of mobile phase, and reconstitution solvents were investigated. The method was fully validated per US-FDA guidelines and demonstrated precision (<13%), accuracy (91-112%), lower limit of quantification (5 ng/mL), linearity over clinically relevant concentrations (R² > 0.999), matrix-effects (93-105%), recoveries (95-106%), and excellent selectivity. The method showed agreement with agar disk diffusion assays for in vitro screening and comparable in vivo performance to LC-MS/MS (Deming Regression, y = 1.010x + 0.123, r = 0.997; Bland-Altman analysis, mean difference was -6.3%; n = 21). Pharmacokinetic parameters suggested superior surface-retentive properties of besifloxacin. Maximum concentrations were 1412 ± 1910 and 0.15 ± 0.12 μg/mL; area under the curve was 1,637 and 1.08 µg·h/g; and half-life was 4.9 and 4.1 h; and pharmacokinetic-to-pharmacodynamic ratios were ≥ 409 and ≤ 17.8 against ocular pathogens in tears and aqueous humor, respectively. This readily available method is sensitive for biosamples and practical for routine use, facilitating besifloxacin therapy development.

01 Sep 2021·Water ResearchQ1 · ENVIRONMENTAL SCIENCE & ECOLOGY

Spatiotemporal profiling of antibiotics and resistance genes in a river catchment: Human population as the main driver of antibiotic and antibiotic resistance gene presence in the environment

Q1 · ENVIRONMENTAL SCIENCE & ECOLOGY

Article

Author: Elder, Felicity C T ; Barden, Ruth ; Gaze, William H ; Kasprzyk-Hordern, Barbara ; Feil, Edward J ; Snape, Jason ; Proctor, Kathryn

Studies to understand the role wastewater treatment plants (WWTPs) play in the dissemination of antibiotics (ABs), and in the emergence of antibiotic resistance (ABR), play an important role in tackling this global crisis. Here we describe the abundance and distribution of 16 ABs, and 4 corresponding antibiotic resistance genes (ARGs), sampled from the influent to five WWTPs within a single river catchment. We consider four classes of antibiotics: fluroquinolones, macrolides, sulfamethoxazole and chloramphenicol, as well the corresponding antibiotic resistance genes qnrS, ermB, sul1 and catA. All antibiotics, apart from four fluroquinolones (besifloxacin, lomefloxacin, ulifloxacin, prulifloxacin), were detected within all influent wastewater from the 5 cities (1 city = 1 WWTP), as were the corresponding antibiotic resistance genes (ARGs). Strong correlations were observed between the daily loads of ABs and ARGs versus the size of the population served by each WWTP, as well as between AB and ARG loads at a single site. The efficiency of ABs and ARGs removal by the WWTPs varied according to site (and treatment process utilized) and target, although strong correlations were maintained between the population size served by WWTPs and daily loads of discharged ABs and ARGs into the environment. We therefore conclude that population size is the main determinant of the magnitude of AB and ARG burden in the environment.

News (Medical) associated with Besifloxacin Hydrochloride

01 Feb 2024

·www.biospace.com

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Dr. Julie Clark, SVP Clinical Development; Dr. Fang Li, SVP Regulatory Affairs, to join February 1st Experienced executives bring extensive track record in products for retinal and ophthalmology diseases MELBOURNE, Australia, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced the appointment of Julie Clark, MD, MS, as Senior Vice President (SVP), Clinical Development, and Fang Li, Ph.D. RAC, as SVP, Regulatory Affairs, effective February 1, 2024. Dr. Clark and Dr. Li will report to Opthea Chief Executive Officer, Frederic Guerard, PharmD, MS, and will join the Opthea Executive Management Team. “It is my great pleasure to welcome two ophthalmology experts, Dr. Clark and Dr. Li, to the Company as we prepare for the next stage in our growth and work towards advancing the development of sozinibercept (OPT-302),” said Dr. Guerard. “Their past contributions to the development and registration of ophthalmology therapies such as IZERVAY™, BEOVU®, and EYLEA®, will be instrumental to the potential success of our lead program investigating sozinibercept, currently in two Phase 3 pivotal trials.” Dr. Clark shared, “I am thrilled to join Opthea as we prepare to complete patient enrollment in the pivotal Phase 3 clinical program for sozinibercept in the first half of 2024. The majority of my career has been dedicated to the clinical development of novel therapies for retinal diseases. Sozinibercept could be the first new drug for wet age-related macular degeneration (AMD) in more than 15 years, with the potential to deliver superior visual gains when administered in combination with standard of care therapy. I look forward to contributing to bringing this novel product candidate to patients with serious retinal disease.” Dr. Li commented, “As we work towards the potential release of topline results for our Phase 3 program in mid-2025, I am excited to apply my expertise to support the development and execution of our regulatory strategy and potential filings for sozinibercept in the U.S. and other markets. I look forward to the opportunity to bring Opthea’s innovative potential medicine through the regulatory process for the benefit of patients with retinal diseases.” Julie Clark, MD, MS With more than 15 years of experience in ophthalmology medical and clinical development, Dr. Clark brings expertise in both early and late-stage programs, regulatory submissions, and approvals. Her contributions include substantial support for the approval and launches of retinal therapies such as EYLEA®, JETREA® and BEOVU®. In Dr. Clark’s most recent position as Vice President Clinical Development at IVERIC bio, Inc., An Astellas Company, she oversaw the development program leading to the August 2023 U.S. Food and Drug Administration (FDA) approval of IZERVAY™, a complement inhibitor approved for the treatment of geographic atrophy secondary to age-related macular degeneration. Dr. Clark previously served as Chief Medical Officer at Adverum Biotechnologies Inc, where she played a crucial role in developing intravitreal delivered gene therapy for retinal diseases. Dr. Clark is a graduate of Wake Forest University and Wake Forest University School of Medicine in Winston-Salem, NC, U.S. Fang Li, PhD, RAC Dr. Li brings over 30 years of expertise in drug development and more than 20 years in regulatory affairs experience. Her experience spans various domains including small molecules, biologics, gene therapy, over-the-counter products, in-vitro diagnostic products and medical devices, with a specific focus on ophthalmology. She has held key roles at prominent ophthalmology companies such as Novartis AG, Alcon Inc., and Bausch + Lomb Corporation. Dr. Li's extensive background includes significant involvement in health authority interactions, U.S. FDA advisory committee meeting preparation and the establishment and leadership of regulatory teams. She has a proven track record of success in obtaining product approvals in the U.S. and other regions. Throughout her career, Dr. Li has played a pivotal role in leading numerous FDA drug approvals, specifically contributing to the approval of ophthalmology products like JETREA®, LOTEMAX® Ointment, SYSTANE® COMPLETE. She has also contributed to the development and registration of other ophthalmology drug products such as BEOVU®, PAZEO®, LOTEMAX® GEL, BESIVANCE®, and VYZULTA®. Fang holds a PhD in Medicinal Chemistry from China Pharmaceutical University, China. About Opthea Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including neovascular (wet) age-related macular degeneration (wet AMD). Opthea’s lead product candidate sozinibercept is being evaluated in two pivotal Phase 3 clinical trials (ShORe, NCT04757610, and COAST, NCT04757636) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care. To learn more, visit and follow us on X and LinkedIn. Inherent risks of Investment in Biotechnology Companies There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments. Forward-looking Statements This ASX announcement contains certain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. The words “expect”, “believe,” “should”, “could”, “may”, “will”, “plan” and other similar expressions are intended to identify forward-looking statements. Forward-looking statements in this ASX announcement include statements regarding expectations on the outcomes of Opthea’s Phase 3 clinical trials of sozinibercept, the potential for sozinibercept as a combination therapy to be the first therapy to achieve superior visual outcomes over anti-VEGF-A monotherapy and improve vision outcomes for patients with wet AMD, the expected timing for completion of enrollment for the Phase 3 studies and topline data, the market opportunity for sozinibercept, and the future performance of Opthea. Forward-looking statements, opinions and estimates provided in this ASX announcement are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current conditions. Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. They involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Opthea and its directors and management and may involve significant elements of subjective judgment and assumptions as to future events that may or may not be correct. These statements may be affected by a range of variables which could cause actual results or trends to differ materially, including but not limited to future capital requirements, the development, testing, production, marketing and sale of drug treatments, regulatory risk and potential loss of regulatory approvals, ongoing clinical studies to demonstrate sozinibercept safety, tolerability and therapeutic efficacy, additional analysis of data from Opthea’s Phase 3 clinical trials, timing of completion of Phase 3 clinical trial patient enrollment and clinical research organization and labor costs, intellectual property protections, and other factors that are of a general nature which may affect the future operating and financial performance of the Company including risk factors set forth in Opthea’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on September 28, 2023 and other future filings with the SEC. Actual results, performance or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. Subject to any continuing obligations under applicable law or any relevant ASX listing rules, Opthea disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this ASX announcement to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any such statement is based, except as otherwise required by applicable law. Authorized for release to ASX by Frederic Guerard, CEO Company & Media Enquiries: Rudi Michelson Monsoon Communications Tel: +61 (0) 3 9620 3333 Investor Enquiries PJ Kelleher LifeSci Advisors Email: pkelleher@lifesciadvisors.com Join our email database to receive program updates: Tel: +61 (0) 3 9826 0399 Email: info@opthea.com Web:

Phase 3Executive ChangeDrug Approval

26 Apr 2023

·www.biospace.com

Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs

Oculis establishes its US headquarters in Boston, MA, a world-renowned biotech hub, to support its continued expansion following OCS listing into NASDAQ Oculis’s finance and development team strengthened by US-based hires, including Dr. Fang Li as Senior Vice President, Regulatory Affairs, who successfully led important FDA new drug approvals in ophthalmology US-based office established ahead of important near-term clinical and late-stage data milestones such as results from Stage 1 of Phase 3 DIAMOND study of OCS-01 in DME and from Phase 3 OPTIMIZE study of OCS-01 in Inflammation and Pain following cataract surgery later in 2023 ZUG, Switzerland, and BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the opening of its Boston, Massachusetts office, expanding its US presence in preparation of becoming an active player in the US market and demonstrating execution of its strategy. Located in the heart of the largest national and global life sciences hub, the new Boston office will serve as a strategic location for Oculis to support its US operations in anticipation of important near-term clinical and late-stage data milestones such as results from Stage 1 of the Company’s Phase 3 DIAMOND study of OCS-01 in DME and the Phase 3 OPTIMIZE study of OCS-01 in Inflammation and Pain following cataract surgery later this year. The expansion of Oculis’s presence in the US accompanies the recent strengthening of its finance and development team. This includes the hiring of Dr. Fang Li as the new US-based Senior Vice President, Regulatory Affairs. Dr. Li brings to Oculis over 25 years of drug development experience, having worked in regulatory affairs for over 20 years with leading ophthalmology companies such as Novartis, Alcon and Bausch & Lomb, among others. She has extensive experience with health authority interactions, FDA advisory committee meeting preparation, and building and leading regulatory teams. She has a proven success record in gaining product approvals in the US and other regions. Throughout her career, she successfully led numerous FDA drug approvals in ophthalmology including for Jetrea, Lotemax Ointment, Systane Complete and worked on several other ophthalmology drug products such as Beovu, Lotemax Gel, Besivance, and Vyzulta. Riad Sherif, MD, CEO of Oculis, said, “Together with the strengthening of our global development team by hiring Dr Fang Li, the opening of our US headquarters is a major milestone for Oculis and represents an exciting new chapter for our team. Boston is a city with a long history of innovation and world-renowned medical center and we are excited to work with the rich pool of talent and partners available in the area, and to take part in the local biotech ecosystem.” About Oculis Oculis is a global biopharmaceutical company (Nasdaq: OCS) purposefully driven to save sight and improve eye care. Oculis’s highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop retinal candidate for diabetic macular edema (DME); OCS-02, a topical eye drop biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis’s goal is to deliver life-changing treatments to patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors. For more information, please visit: Contacts Investor Relations Riad Sherif MD, CEO riad.sherif@oculis.com Ms Sylvia Cheung, CFO sylvia.cheung@oculis.com Media Relations Consilium Strategic Communications Amber Fennell, Tracy Cheung, David Daley oculis@consilium-comms.com Cautionary Statement Regarding Forward Looking Statements This press release contains forward looking statements and information. For example, statements regarding expected future milestones and catalysts; the initiation, timing, progress and results of Oculis’ clinical and preclinical studies; Oculis’ research and development programs, regulatory and business strategy, future development plans, and management; Oculis’ ability to advance product candidates into, and successfully complete, clinical trials; and the timing or likelihood of regulatory filings and approvals, are forward looking. All forward looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ proxy statement and the prospectus for Oculis’ offering, and any other documents filed with the U.S. Securities and Exchange Commission (the “SEC”). Copies of these documents are available on the SEC’s website, Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Executive ChangePhase 3

100 Deals associated with Besifloxacin Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D08872	Besifloxacin Hydrochloride	S01AE08	DB06771

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Conjunctivitis, Bacterial	US	Bausch & Lomb, Inc.	28 May 2009

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Corneal Ulcer	Discovery	US	Bausch & Lomb, Inc.	01 Jul 2013
Lacrimal Duct Obstruction	Discovery	US	Bausch & Lomb, Inc.	01 Sep 2011
Cataract	Discovery	US	Bausch & Lomb, Inc.	01 Feb 2009
acute bacterial conjunctivitis	Discovery	-	Bausch & Lomb, Inc.	01 Jun 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01296542 (CTgov)	Phase 4	Cataract	60	Moxifloxacin Ophthalmic (VIGAMOX)	snugxbeqxo(uqymujbomy) = asjrhyrcdo frzpjnoxdz (omtlkixcmr, khisopxitk - nkonczixtv) View more	-	08 Dec 2020
				Besifloxacin Ophthalmic (Besivance)	snugxbeqxo(uqymujbomy) = xtsttzskke frzpjnoxdz (omtlkixcmr, incpfftzsj - zmfisxzkiw) View more
NCT00348348 \| NCT00622908 \| NCT00347932 (Pubmed \| J Biol Chem)	Phase 2	Conjunctivitis, Bacterial	1,041	Besifloxacin ophthalmic suspension 0.6%	(xckwrtzhcp) = msflzujvoq kedvpqvlzj (alrhbwuelk )	-	01 Jan 2020
				Vehicle	(xckwrtzhcp) = lducwlvxqc kedvpqvlzj (alrhbwuelk )
NCT01296191 (CTgov)	Phase 4	Cataract	120	moxifloxacin (VIGAMOX)	ipuosusroy(vukjzqmoho) = houautvlmj kutqzymmzv (dgdhrhksnd, xdnidgigfr - lqufofnktu) View more	-	29 Oct 2019
				besifloxacin (Besivance)	ipuosusroy(vukjzqmoho) = crbegslige kutqzymmzv (dgdhrhksnd, nwjzfvzhjo - dcxcmujtke) View more
ARVO2019	Not Applicable	Conjunctivitis, Bacterial \| Infectious Diseases	1,041	Besifloxacin Ophthalmic Suspension 0.6%	(fikeiagojs) = feeedsyyyj rtcziymwnk (lytvwjrwth )	-	01 Jul 2019
2018 ARVO Annual Meeting (ARVO2018)	Not Applicable	Bacterial keratitis	-	Besifloxacin Ophthalmic Suspension	(elkufqbibm) = rojaaupnvj awqmpblybg (lwtjfagoom )	Negative	01 Jul 2018
				Fortified Tobramycin + Vancomycin	(elkufqbibm) = zfihcjjlng awqmpblybg (lwtjfagoom )
NCT01431170 (CTgov)	Phase 1	Lacrimal Duct Obstruction	24	Besivance Treatment Group (Besivance Treatment Group)	vzwjhvkrrv(hkybdriium) = cemyruijdt bjhmjozahm (mwmxlgwafp, dtfshjfzwo - gagpsbtlwh) View more	-	09 Jun 2016
				Polytrim Treatment Group (Polytrim Treatment Group)	vzwjhvkrrv(hkybdriium) = fhwwrodmwa bjhmjozahm (mwmxlgwafp, sxrcerhbta - zwvdxnjlvy) View more
NCT01928693 (Eye02, CTgov)	Phase 2	Corneal Ulcer	2	Besivance 0.6% Ophthalmic Suspension (Besivance 0.6% Ophthalmic Suspension)	rxaxuubfpr(exhnihwscc) = rjkgbfabtx sclqtxalax (vfrubtvxmi, jnkaatiubn - yvxwtvrurz) View more	-	13 Aug 2015
				Zymaxid 0.5% Ophthalmic Solution (Zymaxid 0.5% Ophthalmic Solution)	srwhtnjexw(nxguscbaok) = gjokysqcnz lhhdksbfmm (qirxkmjonf, rntsqvoxdp - ptfxmksujw) View more
ARVO2015	Not Applicable	Lacrimal Duct Obstruction	-	Besivance	(tppnikqcgm) = pdsvqomwon eztbsfdrpg (dmlrjfaviq ) View more	-	01 Jun 2015
				Polytrim	(tppnikqcgm) = wutewseify eztbsfdrpg (dmlrjfaviq ) View more
NCT01740388 (CTgov)	Phase 3	Conjunctivitis, Bacterial	136	Besifloxacin (Besifloxacin)	ktniwtwogl(lyumhqdadw) = oqslfylqhn kbyexxwhnx (nmyzwtwaxh, xlpluopidl - lbyuukwtoe) View more	-	17 Sep 2014
				Vehicle (Vehicle)	ktniwtwogl(lyumhqdadw) = nyqlqntzbz kbyexxwhnx (nmyzwtwaxh, xyioihmoxe - hndbhqqoxq) View more
NCT01330355 (CTgov)	Phase 3	Conjunctivitis, Bacterial	33	Besivance (Besivance)	zoxrnbtstn(eierqybxui) = spkqlkbwgu tinxjxkclv (zeamqhhrar, fecjvlosuk - xnhgqxqxdd) View more	-	03 Sep 2014
				Gatifloxacin (Gatifloxacin)	zoxrnbtstn(eierqybxui) = reywwmpfcj tinxjxkclv (zeamqhhrar, pmnjtpnxzo - ysedopuowp) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis